Please assess the completion status of the following clinical trial:

Trial Title: VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \> or = 12 years of age~* NDD-CKD subjects~* Baseline hemoglobin \< or = 11g/dl~* Stable erythropoietin (EPO) status~Exclusion Criteria:~* Known hypersensitivity to ferrous sulfate or IV iron~* Unstable EPO status~* Anemia not related to CKD~* Chronic, serious infection~* Recent IV iron~* Recent blood transfusion~* Recent blood loss~* Need for surgery~* Received investigational drug within 30 days~* Female subjects who are pregnant or lactating

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose (FCM) (Type: EXPERIMENTAL): A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
- Ferrous Sulfate tablets (Type: ACTIVE_COMPARATOR): 325 mg/TID x 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).